Sofiva Genomics Co.,Ltd.

TPEX:6615 Rapporto sulle azioni

Cap. di mercato: NT$984.7m

Sofiva GenomicsLtd Performance dei guadagni passati

Il passato criteri di controllo 1/6

Sofiva GenomicsLtd's earnings have been declining at an average annual rate of -15.7%, while the Healthcare industry saw earnings growing at 6.8% annually. Revenues have been declining at an average rate of 1.1% per year. Sofiva GenomicsLtd's return on equity is 4%, and it has net margins of 5.2%.

Informazioni chiave

-15.7%

Tasso di crescita degli utili

-15.9%

Tasso di crescita dell'EPS

Healthcare Crescita del settore9.1%
Tasso di crescita dei ricavi-1.1%
Rendimento del capitale proprio4.0%
Margine netto5.2%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Apr 14
Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Mar 18
Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Feb 24
Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 27
Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)

Jan 07
Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)

A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Dec 15
A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend

Nov 24
Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend

Ripartizione dei ricavi e delle spese

Come Sofiva GenomicsLtd guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

TPEX:6615 Ricavi, spese e utili (TWD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 24478251328
31 Mar 24475201349
31 Dec 234671213610
30 Sep 234723413512
30 Jun 234733113413
31 Mar 234833313511
31 Dec 224964313510
30 Sep 22501371358
30 Jun 22506491357
31 Mar 22510621328
31 Dec 215085713111
30 Sep 215075313012
30 Jun 215054412613
31 Mar 214943312512
31 Dec 204893512210
30 Sep 20489371218
30 Jun 20497481237
31 Mar 20506591238
31 Dec 19509631238
30 Sep 19504611198
30 Jun 19486511129
31 Mar 19469491079
31 Dec 18459471019
30 Sep 18451461008
30 Jun 18446481016
31 Mar 1843845976
31 Dec 1742445954
30 Sep 1741048914
30 Jun 1739849876
31 Mar 1738845846
31 Dec 1638443837
30 Jun 1637333809
31 Mar 1635625798
31 Dec 1534416788
31 Dec 1429523660
31 Dec 13154-23400

Guadagni di qualità: 6615 has high quality earnings.

Margine di profitto in crescita: 6615's current net profit margins (5.2%) are lower than last year (6.6%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: 6615's earnings have declined by 15.7% per year over the past 5 years.

Accelerare la crescita: 6615's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Guadagni vs Settore: 6615 had negative earnings growth (-19%) over the past year, making it difficult to compare to the Healthcare industry average (3.6%).


Rendimento del capitale proprio

ROE elevato: 6615's Return on Equity (4%) is considered low.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate